casper rokx

289 Pages·2016·18.56 MB·English

CASPER ROKX
H I V: Treatment
and Comorbidity

CASPER ROKX
H I V: Treatment
and Comorbidity
HIV: Treatment and Comorbidity
ISBN: 978-94-6169-862-9
The studies reported in this thesis were performed at the departments of Internal
Medicine, Medical Microbiology and Infectious Diseases and Viroscience of the Eras-
mus MC University Medical Center, Rotterdam, the Netherlands, at the department
of Pharmacology of the Radboud University Medical Center, Nijmegen, the Nether-
lands, at the Stichting HIV Monitoring, Academic Medical Center, Amsterdam, the
Netherlands. The research (I13018) on the ATHENA Cohort Study is maintained by
the Stichting HIV Monitoring, supported by the Dutch Ministry of Health via the
National Institute for Public Health and Environment (RIVM).
Financial support for the reproduction of this thesis was provided by Gilead Sciences,
Janssen-Cilag BV, Boehringer-Ingelheim BV and Virology Education.
Cover design, lay-out, printing: Optima Grafische Communicatie, Rotterdam, the
Netherlands.
© Casper Rokx, 2016.
No part of this thesis may be reproduced, stored, or transmitted in any form or by any
means, without permission of the author.
HIV: Treatment and Comorbidity
HIV: Behandeling en Comorbiditeit
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus
prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
dinsdag 14 juni 2016 om 11.30 uur
door
Casper Rokx
geboren te Groningen
PromoTIeCommIssIe
Promotor: Prof.dr. A. Verbon
Overige leden: Prof.dr. C.A.B. Boucher
Prof.dr. J.L.C.M. van Saase
Prof.dr. P. Reiss
Copromotor: Dr. B.J.A. Rijnders
Hetzelfde zien,
maar het zo
zien, zoals nog
niemand het zag
Jules Deelder

Table of ConTenTs
1 General introduction and outline of the thesis 11
Part 1 Efficacy of first-line antiretroviral treatment
2 Increased virological failure in naive HIV-1-infected patients taking 39
lamivudine compared with emtricitabine in combination with
tenofovir and efavirenz or nevirapine in the Dutch nationwide
ATHENA cohort.
Clinical Infectious Diseases, 2015.
3 Virological responses to lamivudine or emtricitabine when 67
combined with tenofovir and a protease inhibitor in treatment
naive HIV-1 patients in the Dutch ATHENA cohort.
HIV Medicine, 2016.
Part 2 Antiretroviral treatment switch strategies
4 The efficacy, pharmacokinetics, and safety of a nevirapine to 91
rilpivirine switch in virologically suppressed HIV-1-infected
patients.
Journal of Acquired Immune Deficiency Syndromes, 2015.
5 Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1- 103
infected patients with an isolated K103N mutation acquired during
prior nonnucleoside reverse transcriptase inhibitor therapy.
HIV Medicine, 2014.
6 Dolutegravir as maintenance monotherapy: first experiences in 113
HIV-1 patients.
Journal of Antimicrobial Chemotherapy, 2016.
Part 3 Comorbidity during antiretroviral treatment
7 Renal toxicity of concomitant exposure to tenofovir and inhibitors 125
of tenofovir’s renal efflux transporters in patients infected with
HIV type 1.
The Journal of Infectious Diseases, 2016.
8 Lipids and cardiovascular risk after switching HIV-1 patients 143
on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/
emtricitabine/tenofovir-DF.
AIDS Research and Human Retroviruses, 2015.
9 Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: 155
experience with 10 patients.
Clinical Infectious Diseases, 2013.
10 Treatment of multicentric Castleman’s disease in HIV-1 infected 165
and uninfected patients: a systematic review.
Netherland Journal of Medicine, 2015.
Part 4 Perspectives
11 Roundtable on the future management of HIV. 183
Journal of Virus Eradication, 2015.
12 Summarizing discussion 207
13 Nederlandse samenvatting 225
14 References 235
15 Antiretroviral drug abbreviations 271
Publications 272
PhD portfolio 276
Curriculum vitae 280
Dankwoord 281